Therapeuticsmd, INC

TherapeuticsMD announced its first quarter 2026 financial results, reporting a net income of $103 thousand and license revenues of $724 thousand, while continuing to evaluate strategic alternatives.

TherapeuticsMD, Inc. announced the appointment of Carr, Riggs & Ingram, L.L.C. as its new independent registered public accounting firm, effective January 15, 2026.

TherapeuticsMD, Inc. shareholders approved all five proposals at its 2025 Annual Meeting, including the election of directors and an increase in authorized common stock.

TherapeuticsMD, a pharmaceutical royalty company, reported a net income of $50 thousand for the third quarter of 2025, a significant improvement from a loss in the prior year.

TherapeuticsMD, a pharmaceutical royalty company, reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss in the prior year, driven by increased license revenue and reduced operating expenses.

TherapeuticsMD reported a net loss of $636,000 for Q1 2025, with license revenue increasing by 25.8% and the company continuing to evaluate strategic alternatives.

TherapeuticsMD, Inc. transitioned to a pharmaceutical royalty company, reporting increased license revenue and net income for the first quarter of 2026, while navigating ongoing legal disputes.

TherapeuticsMD reported a net income of $152,000 for Q3 2025 and $50,000 for the first nine months, a significant improvement from prior year losses, despite ongoing legal disputes and a 'going concern' warning.

TherapeuticsMD, a pharmaceutical royalty company, reported a significant increase in Q2 2025 license revenue and a return to net income from continuing operations, despite ongoing legal disputes and going concern doubts.

TherapeuticsMD, now a royalty-based pharmaceutical company, reports increased license revenue for Q1 2025 but faces a lawsuit with Mayne Pharma and going concern uncertainties.

TherapeuticsMD's third quarter 2024 results show increased license revenue and reduced operating expenses as the company continues its transition to a pharmaceutical royalty business.

TherapeuticsMD's second quarter results show a net loss of $1.09 million as the company continues its transition to a pharmaceutical royalty business.

TherapeuticsMD, a pharmaceutical royalty company, reported reduced net losses in 2025 but faces substantial doubt about its ability to continue as a going concern due to ongoing legal disputes and liquidity challenges.

TherapeuticsMD reports reduced net loss and increased license revenue in 2025, but faces substantial doubt about its going concern status due to ongoing legal disputes and liquidity challenges.

TherapeuticsMD files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

TherapeuticsMD, now a royalty-focused company, faces going concern doubts despite revenue increase and cost reductions following its strategic shift in 2022.

TherapeuticsMD files an amendment to its annual report to include information previously omitted regarding directors, executive compensation, and related matters.

TherapeuticsMD transitioned to a pharmaceutical royalty company in 2022, licensing its products and reporting a net loss of $10.3 million for 2023.

TherapeuticsMD Director Tommy G. Thompson acquired 8,400 shares of common stock at $1.6703 per share in a pre-planned transaction.

TherapeuticsMD Director Gail K. Naughton was granted 8,500 restricted stock units, vesting on November 3, 2028.

TherapeuticsMD Director Tommy G. Thompson was granted 8,500 restricted stock units, which are set to vest on November 3, 2028.

TherapeuticsMD Director Cooper C. Collins was granted 8,500 Restricted Stock Units, which will vest on November 3, 2028.

TherapeuticsMD CEO Marlan D. Walker reported the acquisition of 67,492 non-qualified stock options with an exercise price of $1.15, vesting on November 3, 2025.

Director Tommy G. Thompson reports purchasing 325 shares of TherapeuticsMD, Inc. at an average price of $1.0018 on April 14, 2025.

TherapeuticsMD, Inc. announced its Annual Meeting of Stockholders for December 15, 2025, outlining key proposals including director elections, executive compensation, auditor ratification, and an increase in authorized common stock.

TherapeuticsMD, Inc. announced its Annual Meeting of Stockholders for December 15, 2025, to vote on director elections, executive compensation, auditor ratification, and a significant increase in authorized common stock.

TherapeuticsMD, Inc. will hold its annual meeting of stockholders on December 5, 2024, to elect directors, approve executive compensation, and ratify the appointment of an independent auditor.

TherapeuticsMD, Inc. will hold its annual meeting of stockholders virtually on December 5, 2024, to elect directors, approve executive compensation, and ratify the appointment of an independent auditor.

Baselake Partners, LP and associated entities have reported a 5.2% passive ownership stake in TherapeuticsMD, Inc., totaling 607,181 shares.

Clearline Capital LP, Clearline Capital LLC, and Marc Majzner have jointly disclosed a passive 5.5% beneficial ownership stake in TherapeuticsMD, Inc., totaling 635,222 shares as of December 31, 2024.